A qualitative study delves into the realm of cardiac palliative care programs, revealing their organizational structures, services, and encountered challenges. Learn how these programs address the unique needs of patients with advanced heart failure and guide the development of future initiatives.
Read MoreAnumana’s electrocardiogram (ECG) artificial intelligence (AI) algorithm, developed in collaboration with Mayo Clinic, has received FDA’s breakthrough device designation for early identification of cardiac amyloidosis.
Read MoreUnveiling the Potential: Angiotensin-Neprilysin Inhibition in Heart Failure In the realm of medical technology, breakthroughs often pave the way for innovative treatments that transform patient care. A recent randomized trial,...
Read MoreThe CLEAR Outcomes Trial: Exploring Bempedoic Acid’s Impact on Cardiovascular Events The CLEAR Outcomes trial, conducted across 1,250 centers in 32 countries, aimed to investigate the efficacy and safety of bempedoic acid...
Read MoreA recent randomized controlled trial has shed light on the treatment options for stroke patients without occlusion of large or medium-sized arteries. Findings indicate that tirofiban, an intravenous glycoprotein IIb/IIIa receptor inhibitor, surpasses low-dose aspirin in achieving excellent outcomes.
Read More